← Leaderboards
Charles D Howell
University Of Maryland Baltimore
$4,304,760
Attributed
$4,304,760
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $697.3K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$4,304,760 · 8
By mechanism
U01$1,275,035 · 1
R01$1,031,179 · 2
K24$943,800 · 1
M01$650,084 · 3
R21$404,662 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- William Albert Blattner$260,131,047
- Alonso Heredia$3,865,060
Others in their field
Top investigators on “Caucasian American”
- James D Crapo · University Of Colorado Denver$53,843,644
- Edwin K Silverman · Brigham And Women'S Hospital$45,010,816
- Gerard David Schellenberg · University Of California San Diego$41,561,356
- James J Lah · Emory University$38,151,704
- Ronald M Krauss · University Of Calif-Lawrenc Berkeley Lab$35,314,126
- David Couper · Univ Of North Carolina Chapel Hill$30,911,815
Research focus
Caucasian AmericanRibavirinAfrican AmericanRacial /Ethnic DifferenceChronic Disease /DisorderClinical TrialsInterferon AlphaHepatitis CPatient Oriented ResearchHepatitis C VirusImmunotherapyGenotypeResponseRaceClinical ResearchLiver CirrhosisDrug KineticsHealth DisparityCombined Modality TherapyIncidenceEtiologyInterferonsPrimary Carcinoma Of The Liver CellsUnited States
Grant awards (21)
Racial Disparities in Liver Diseases$200,076
K24 · FY2009 · DK · contact PI
RIBAVIRIN PHARMACOKINETICS, RACE AND OUTCOME OF HEPATITIS C TREATMENT$31,511
M01 · FY2009 · RR · contact PI
Racial Disparities in Liver Diseases$194,250
K24 · FY2008 · DK · contact PI
Ribavirin Pharmacokinetics, Race and HCV Treatment$181,912
R21 · FY2008 · DK · contact PI
Ribavirin Pharmacokinetics, Race and HCV Treatment$222,750
R21 · FY2007 · DK · contact PI
Racial Disparities in Liver Diseases$188,596
K24 · FY2007 · DK · contact PI
Racial Disparities in Liver Diseases$183,105
K24 · FY2006 · DK · contact PI
Predicting Outcomes of Peginterferon & HCV$145,010
R01 · FY2006 · DK · contact PI
STUDY OF VIRAL RESISTANCE TO ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C (VIRAHEP)$23,766
M01 · FY2006 · RR · contact PI
Predicting Outcomes of Peginterferon &HCV$222,750
R01 · FY2005 · DK
THE BALTIMORE VIRAHEP-C CLINICAL CENTER$191,728
M01 · FY2005 · RR
Racial Disparities in Liver Diseases$177,773
K24 · FY2005 · DK
Baltimore VIRAHEP-C Clinical Center$105,000
U01 · FY2005 · DK
Viral Resistance to Antiviral Therapy for Hepatitis C$403,079
M01 · FY2004 · RR
Predicting Outcomes of Peginterferon &HCV$222,750
R01 · FY2004 · DK
Baltimore VIRAHEP-C Clinical Center$175,000
U01 · FY2004 · DK
Baltimore VIRAHEP-C Clinical Center$350,000
U01 · FY2003 · DK
Baltimore VIRAHEP-C Clinical Center$370,000
U01 · FY2002 · DK
Baltimore VIRAHEP-C Clinical Center$275,035
U01 · FY2001 · DK
PATHOGENESIS OF CHRONIC GRAFT VERSUS HOST LIVER DISEASE$224,596
R01 · FY2001 · DK
PATHOGENESIS OF CHRONIC GRAFT VERSUS HOST LIVER DISEASE$216,073
R01 · FY2000 · DK